Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Aybintio (bevacizumab biosimilar)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

3SBio, Mundipharma, Samsung

Drug class:

VEGF-A inhibitor

Related drugs:

‹

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

bevacizumab (416)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

bevacizumab-bvzr (8)

aflibercept intravitreal (7)

Krabeva (bevacizumab biosimilar) (7)

Byvasda (bevacizumab biosimilar) (4)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

›

No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval erlotinib + Aybintio (bevacizumab biosimilar) Sensitive : A1	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval erlotinib + Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A2 - Guideline Aybintio (bevacizumab biosimilar) Sensitive : A2	Aybintio (bevacizumab biosimilar) Sensitive: A2 - Guideline Aybintio (bevacizumab biosimilar) Sensitive : A2